Ben Richardson, CEO at SulNOx, confident they can cost-effectively decarbonise commercial shipping. Watch the video here.
Evening El, interesting trading pattern mix of scared and opportunistic investors. Do we know the late notified big sell from yesterday...wasn’t me. What is your take on the last day or so? Personally waiting for details from the EGM, ought to be a trading update imo, FDBK need to explain their targets going forward if they want to retain/attract serious investors imo.
Hi Chippy, have a look at the last rns where it states �Company has posted to its shareholders a circular containing a notice convening the General Meeting (the "Circular"), the purpose of which is to seek renewed authorities to allow the directors to issue ordinary shares for cash on a non-pre-emptive basis as the authority granted at the last Annual General Meeting has largely been utilised. The Circular will be available on the Company's website shortly at www.fbk.com.� The last fundraise has been used up and with new appointments it is likely imo that cashflow will be a problem hence the BOD seeking approval to raise further funds. I am STILL optimistic going forward as I do believe the Board have a clear strategy with confidence that FDBK will be successful, but I think there will be a pullback pending the General Meeting announced. As always, my own opinion only, dyor.
Yeah not good news Neill, much depends upon your timeframe though. This is still a very experienced, very well connected BOD though and they will have thought this through a while ago imo and in spite of the fundraise the CEO still states he intends to build a world class company in its field. Given that, and I do hope my faith is not misplaced, I do think within 2 years FDBK will be making substantial profits. If not then my belief will have cost me dearly! Each investor must make his/her own decision based upon his/her own circumstances. Never has dyor had more meaning...GLA.
Hi WHL, be interesting to see if there is a recovery tomorrow or if the downward trend continues, volume could be telling too. If the BOD are getting ready for clinical sales then even with dilution there will be a point where the becomes a bargain, such are the rewards. Difficult to judge but for me I would certainly want more around the 2p mark, dyor obviously.
message from share trades reacting to the rns with good buys and chunky sells. Fwiw my take is that if FDBK succeed in selling clinical versions of TexRAD internationally then the potential market is so big that will mitigate present share dilution. BUT that does require a vote of confidence in the BOD to deliver, and I would like to know how big the proposed dilution will be and whether all/most of the new shares will be taken by directors. The latter point could be a positive as they do not have a lot of skin at present. The tone of David Crabbs comments appeared very positive to me and I do believe he now has a firm strategy to take TexRAD to the clinical market. Given the potential size of the market and profits I can see this being a 50-100m mcap in time (?2-3yrs) if they get it right. As with most things with FDBK history tells me nothing will be straightforward but at present I am inclined to believe this BOD know what they are doing. Without the distraction of TB, and depending upon the size of the fundraise, there should not be more deterrents to the sp. my view only so please dyor, I am positive but I can understand those less so.
Hi Bo, that gives me 9 months to dust off the beads and incense but can we make it a couple of days at say Glastonbury instead? I don�t think there is much chance of this BOD not delivering though, behind the scenes I reckon they have all the ducks lined up. Next RNS could be the propellant....let us hope.
Morning Botak, the science is way beyond my meagre understanding but the message is clear. TexRAD has a very important role to play when using AI to better aid clinicians in their diagnosis and treatment recommendations. The market is potentially huge and when taken up globally I find it difficult to understand how valuable FDBK could become. Current sp levels will seem crazy in a year or two imo, especially given the profit margin on software.
Thanks El pretty much reflects my thinking, when sales decline there will be a rerate to satisfy buying appetite. Interesting TexRAD Gastric note, wonder if this testing is ahead of Liver? If Hors is right and the CEO gets clinical sales moving together with another CE then your year end prediction might outdo mine yet, interesting few months ahead. Casting another glance at the piggy bank methinks.
Hi El, we have seen quite remarkable volumes on various days compared to what was normal a year or two back. What do you think is driving this considering at present the sp has not really responded? I realise the BOD is very different, TB is all but gone, Lung has CE etc, but the sp has not responded in kind along with the volume. My opinion is that a rerate must be on the cards to reflect pent up demand?
Agree with you Brooko19 mostly, not too sure about the FTSE bit but time will tell, there is no doubting the pedigree of FDBK BODs. Given the ridiculously small mcap at present there is no way they would be here if they did not think there was a compelling prospect of growing the Company into a major sector player. They are not here to play games. Extensive dilligance would have been done and then they joined, that to me is a real endorsement of the future. I am confident that a strategy is now in play which will see FDBK both profitable and growing rapidly within the next year. With TB pressure largely removed I think the sp is now in bargain basement territory....but not for long! All my opinion of course so dyor.
Evening Hors, El....my depth of technical knowledge for all things chartist or TexRAD scientific would easily fit on less than half the proverbial! I do however pay great attention to those who know better and generally that mirrors sentiment on here, I am therefore greatly encouraged going forward and a mcap of �50-100m in the next 2 years will do nicely thank you. Once we get an sp of say 10p then the clinical sales/product development leading to that will give the sp a life of its own and growth could be rapid. My thoughts only, dyor plse.
Morning El, beautiful day hope you are enjoying. Nic�s thoughts echo my 7p target for year end, whether that is a comfort I am not sure. She predicts one more little pull back to 2.2p then a rise to 4.5p and the next leg up after to 6.25p. After that we should have a springboard to take the sp where clinical revenues drive it, growth would then be significant into next year imo, just a little more patience meantime.
Afternoon Bo, happy to pack my case....would like a bit more than. 10p though to buy the ticket. Agree with El, this is now a serious BOD, no way will this be allowed to fail. Just a question of investor patience now (we are good at that aren�t we), once clinical sales start and the TexRAD worth is seen in action the sp will not know how high to go, but it should all be upward, GLA.
Hi Botak hope you are well. TB is now a spent force in terms of being able to seriously damage the sp long term as he has for much of the last year. So now we just need a supply of good news leading hopefully to confirmation of integration to clinical sales. That leads directly to the bottom line and the sp would respond very strongly. I�m confident we now have a very commercially minded BOD able to drive the business so all to play for imo...the next few months leading up to the Resukts could be very interesting imo.
Hi Stu, anything possible. Certain to be a big rise imo but how much might depend upon the detail given ie: will any production/income figs be given, what is expected profit level, will the format apply to other Provinces, is this a template for other countries etc. It should be transformational to VRS but market reaction can be a fickle beast. Hopefully not long to wait.
Morning El, I do like a confident statement....how many multiples of 10p? It will get there over the next year or two imo but at what price for the TO? Be nice to see the sp settle out of the 2s for a change, happy still with my 7p at year end, everyone in profit!
Evening Hors, fine thanks hope you are enjoying the sun. I guess if TexRAD Lung is to receive UK clinical sales then the Alliance trials will report successfully in the near future? At some stage it has to happen as research sales will not propel FDBK to profitability on their own. I remain confident but would be happier with the sp nearer 5p, from there it is a springboard with little from TB to stop it.